40,124 Shares in Edwards Lifesciences Corporation $EW Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, Holdings Channel reports. The fund acquired 40,124 shares of the medical research company’s stock, valued at approximately $3,630,000.

A number of other hedge funds also recently added to or reduced their stakes in EW. Norges Bank acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $803,686,000. Conway Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the second quarter worth $954,000. TD Asset Management Inc increased its holdings in shares of Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after purchasing an additional 47,051 shares during the period. Intech Investment Management LLC increased its holdings in shares of Edwards Lifesciences by 22.2% during the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after purchasing an additional 12,591 shares during the period. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at about $1,626,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,570 shares of company stock worth $2,219,390 in the last three months. 0.31% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on EW shares. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Mizuho raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Evercore reissued an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Barclays restated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Stock Performance

Shares of EW opened at $90.02 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm’s 50 day moving average is $89.12 and its 200-day moving average is $84.63. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The stock has a market capitalization of $51.83 billion, a P/E ratio of 51.74, a P/E/G ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period last year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.